<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00288236</url>
  </required_header>
  <id_info>
    <org_study_id>EFC5593</org_study_id>
    <nct_id>NCT00288236</nct_id>
  </id_info>
  <brief_title>Study Evaluating Rimonabant Efficacy in Insulin-Treated Diabetic Patients(ARPEGGIO)</brief_title>
  <official_title>A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Fixed-Dose Study Evaluating the Effect of One Dose of Rimonabant (20 mg/Day) on Glycemic Control in Type 2 Diabetic Patients Inadequately Controlled With Insulin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary: Effect on HbA1c over 48 weeks in insulin-treated patients with type 2 diabetes&#xD;
&#xD;
      Secondary: Effect on glucose, total daily insulin dose, body weight, waist circumference,&#xD;
      HDL-cholesterol, triglycerides - Safety, tolerability&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The total duration of the study will be up to 360 days including screening period (up to 14&#xD;
      days) and double-blind treatment period (approximately 11 months).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute change in HbA1C from baseline to Week 48</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting glucose, total daily insulin dose, body weight, waist circumference, HDL-cholesterol, triglycerides, safety (physical examination, vital signs, laboratory tests, adverse events).</measure>
  </secondary_outcome>
  <enrollment type="Actual">368</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rimonabant (SR141716)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients aged greater than or equal to 18 years.&#xD;
&#xD;
          -  Diagnosis of type 2 diabetes as defined by WHO criteria.&#xD;
&#xD;
          -  Type 2 diabetes treated with insulin for at least 3 months (insulin dose of at least&#xD;
             30 U/day for at least 4 weeks).&#xD;
&#xD;
          -  HbA1C greater than or equal to 7%.&#xD;
&#xD;
          -  Having signed the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        General:&#xD;
&#xD;
          -  Weight loss &gt; 5 kg within 3 months prior to screening visit.&#xD;
&#xD;
          -  Pregnancy or lactation.&#xD;
&#xD;
          -  Absence of medically approved contraceptive methods for females of childbearing&#xD;
             potential.&#xD;
&#xD;
          -  Administration of other investigational drugs within 30 days prior to screening visit.&#xD;
&#xD;
          -  Previous participation in a Rimonabant study.&#xD;
&#xD;
          -  Presence or history of allergic reaction or intolerance to multiple drugs.&#xD;
&#xD;
        Related to endocrine and metabolic disorders:&#xD;
&#xD;
          -  Presence of any clinically significant endocrine disease according to the&#xD;
             Investigator.Note: euthyroid patients on replacement therapy will be included if the&#xD;
             dosage of thyroxine is stable for at least 3 months prior to screening visit.&#xD;
&#xD;
          -  Fasting C-peptide &lt; 1.0 ng/mL.&#xD;
&#xD;
        Related to other disorders:&#xD;
&#xD;
          -  Presence of any severe medical or psychological condition that in the opinion of the&#xD;
             Investigator would compromise the patient's safety or successful participation in the&#xD;
             study.&#xD;
&#xD;
          -  Presence or history of cancer within the past 5 years with the exception of adequately&#xD;
             treated localized basal cell skin cancer or in situ uterine cervical cancer.&#xD;
&#xD;
        Related to laboratory findings:&#xD;
&#xD;
          -  Positive test for hepatitis B surface antigen and/or hepatitis C antibody.&#xD;
&#xD;
          -  Abnormal TSH level (TSH &gt; ULN or &lt; LLN).&#xD;
&#xD;
          -  Positive urine pregnancy test.&#xD;
&#xD;
        Related to previous or concomitant medications:&#xD;
&#xD;
          -  Antidiabetic drugs other than insulin within 3 months prior to screening visit.&#xD;
&#xD;
          -  Drugs affecting weight (e.g., sibutramine, orlistat, herbal preparations, etc).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ICD CSD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Lane Cove</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Laval</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Providencia</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Gouda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Midrand</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Guildford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <study_first_submitted>February 6, 2006</study_first_submitted>
  <study_first_submitted_qc>February 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2006</study_first_posted>
  <last_update_submitted>April 6, 2009</last_update_submitted>
  <last_update_submitted_qc>April 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2009</last_update_posted>
  <responsible_party>
    <name_title>ICD Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <keyword>Type 2 diabetes mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rimonabant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

